Hansoh Pharma’s dual‑biased GLP‑1/GIP agonist olatorepatide achieves 19.3% weight loss at week 48, signalling a new contender in the obesity drug market
Executive summary: Hansoh Pharma reported Phase III results for its investigational dual‑biased GLP‑1/GIP agonist olatorepatide, demonstrating a mean 19.3% weight loss at week 48 in the EASD 2026 presentation. The efficacy level rivals that of approved obesity therapies and indicates Hansoh may have a viable candidate to capture share in the growing anti‑obesity market.
Who is involved: Hansoh Pharma (sponsor), clinical trial investigators, and the European Association for the Study of Diabetes (EASD) forum.
Likely next: Further safety analysis, potential regulatory discussions with the FDA/EMA, and preparation for a possible NDA submission in 2027 if data remain supportive.
At the EASD 2026 meeting in Milan, Hansoh Pharma presented Phase III data showing that participants receiving olatorepatide lost an average of 19.3% of body weight after 48 weeks. The result places the molecule in the same efficacy range as leading dual‑agonist candidates such as tirzepatide. Analysts note that if the safety profile remains favorable, the data could support a future NDA filing and shift competitive dynamics in the GLP‑1/GIP space.
What's next — scenarios
Base: continued development toward NDA (50%)
Hansoh advances olatorepatide into pivotal Phase III completion and targets an NDA filing in 2027, adding a new dual‑agonist to the obesity portfolio.
- Positive safety read‑out from ongoing Phase III extension (expected Q2 2027)
- FDA pre‑NDA meeting granted (anticipated Q4 2026)
- Manufacturing scale‑up milestones met (Q1 2027)
Upside: accelerated approval based on efficacy (30%)
Regulators grant accelerated approval or breakthrough therapy designation, allowing early market entry in 2026‑2027 and rapid revenue generation.
- EMA/PRIME eligibility confirmed (by Nov 2026)
- Interim analysis shows ≥20% weight loss with acceptable safety (by Dec 2026)
- Fast‑track designation awarded (by Jan 2027)
Downside: safety concerns halt progression (20%)
Emerging safety signals lead to clinical hold or trial suspension, delaying or terminating development.
- Detection of serious adverse events >2% in safety review (by Jan 2027)
- Advisory committee raises safety concerns (Feb 2027)
- Regulatory request for additional preclinical data (Mar 2027)
Timeline
- — 19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD (PR Newswire)
Analysis — what this means
Sectors affected
- Obesity therapeutics (GLP‑1/GIP dual agonists)
- Biopharmaceutical R&D spending
Key entities
Sources
- 19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD — PR Newswire
Related cases
- Sibionics and PharmaSens announce exploration of integrating continuous glucose sensing with automated insulin delivery at EASD 2026
- Sinocare launches integrated chronic disease management solutions at EASD 2026, signaling expansion in digital health for diabetes care
- Eli Lilly accelerates cardiometabolic leadership with pivotal new clinical data presentation at EASD 2026
- Ascletis claims its oral ASC36_35 FDC outperforms eloralintide/tirzepatide combo in preclinical obesity model, positioning it as a potential next‑generation weight‑loss therapy